Lineage Cell Therapeutics Inc (LCTX) — Cash Flow Quality Index
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Quality Index of -2.76x as of December 2020. Operating cash flow of $-5.64 Million is below net income of $2.04 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore investment intensity of Lineage Cell Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Lineage Cell Therapeutics Inc Cash Flow Quality Index (2016–2016)
Historical Cash Flow Quality Index for Lineage Cell Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Lineage Cell Therapeutics Inc (LCTX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Lineage Cell Therapeutics Inc (2016–2016)
Year-by-year earnings quality comparison for Lineage Cell Therapeutics Inc. For live market cap and the full company financial profile, see Lineage Cell Therapeutics Inc market cap and net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -2.27x | $-42.33 Million | $18.62 Million | — |